Summary of debate at 2026 Chimeric Therapeutics (CHM) EGM
April 18, 2026
Below is a summary of the discussion at the Chimeric Therapeutics (CHM) 11am hybrid EGM in Carlton on April 17 2026 at level 3, 62 Lygon St and via Lumi platform to approve 7 items including adviser options and a share consolidation. Attended in person. Latest balance sheet shows $87m in accumulated losses and negative equity of $3m. Market cap $6.6m on EGM day. Bought 250,000 units at 0.002c on March 19. See notice of meeting and voting results. The proxies were not disclosed early in the formal addresses.
Q1.
Answer: The chair... Watch video of exchange via Twitter.
Q2.
Answer: The chair... Watch video of exchange via Twitter.
Q3.
Answer: The chair... Watch video of exchange via Twitter.
Q4.
Answer: The chair... Watch video of exchange via Twitter.
Copyright © 2026 The Mayne Report. All rights reserved
